[Parkinsonism possibly caused by cinnarizine]. 1985

J F Martí Massó, and N Carrera, and E de la Puente

UI MeSH Term Description Entries
D008297 Male Males
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D002936 Cinnarizine A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS. 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine,Cinarizina Inkey,Cinarizina Ratiopharm,Cinarizine,Cinazière,Cinna,Cinnarizin AL,Cinnarizin Siegfried,Cinnarizin Von Ct,Cinnarizin-Ratiopharm,Cinnarizine L-Tartrate,Cinnarizine L-Tartrate (1:1),Cinnarizine, (E)-Isomer,Cinnarizine, Dihydrochloride,Cinnipirine,Cisaken,Dimitronal,R-516,Stugeron,Stugeron Forte,Cinnarizin Ratiopharm,Cinnarizine L Tartrate,Dihydrochloride Cinnarizine,L-Tartrate, Cinnarizine,R 516,R516,Von Ct, Cinnarizin
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

J F Martí Massó, and N Carrera, and E de la Puente
April 1992, Clinical neuropharmacology,
J F Martí Massó, and N Carrera, and E de la Puente
September 1988, BMJ (Clinical research ed.),
J F Martí Massó, and N Carrera, and E de la Puente
May 1999, Movement disorders : official journal of the Movement Disorder Society,
J F Martí Massó, and N Carrera, and E de la Puente
May 1998, Movement disorders : official journal of the Movement Disorder Society,
J F Martí Massó, and N Carrera, and E de la Puente
January 1999, Revista de neurologia,
J F Martí Massó, and N Carrera, and E de la Puente
January 2014, Journal of Parkinson's disease,
J F Martí Massó, and N Carrera, and E de la Puente
November 1995, Biochemical pharmacology,
J F Martí Massó, and N Carrera, and E de la Puente
March 2017, European journal of clinical pharmacology,
J F Martí Massó, and N Carrera, and E de la Puente
January 2022, Journal of Ayub Medical College, Abbottabad : JAMC,
J F Martí Massó, and N Carrera, and E de la Puente
June 1999, The Annals of pharmacotherapy,
Copied contents to your clipboard!